1-(4-nitrobenzenesulfonyl)piperidin-4-ylamine | 883106-51-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-nitrobenzenesulfonyl)piperidin-4-ylamine
• 英文别名: 1-(4-nitrophenylsulfonyl)piperidin-4-amine；1-(4-nitro-benzenesulfonyl)-piperidin-4-ylamine；1-(4-Nitrobenzenesulfonyl)piperidin-4-amine；1-(4-nitrophenyl)sulfonylpiperidin-4-amine
• CAS: 883106-51-2
• 化学式: C₁₁H₁₅N₃O₄S
• 分子量: 285.324
• InChiKey: ZUHHEKCZETVJIM-UHFFFAOYSA-N

物化性质

• 沸点：
  468.0±55.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-nitrobenzenesulfonyl)piperidin-4-ylamine 在 tris-(dibenzylideneacetone)dipalladium(0) 铁粉 、 氯化铵 、 caesium carbonate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 N-{1-[4-(Isoquinolin-3-ylamino)-benzenesulfonyl]-piperidin-4-yl}-acrylamide
  参考文献：
  名称：

  TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

  摘要：

  本文提供了某些化合物和药用盐。还提供了包含至少一种化合物或药用盐以及一个或多个药用载体的药物组合物。描述了治疗对转谷氨酰胺酶TG2活性抑制敏感的某些疾病状态的方法。这些疾病状态包括亚型汉廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化合物或药用盐作为单一活性剂或与一个或多个其他治疗剂结合使用至少一种化合物或药用盐。

  公开号：

  US20120302539A1
• 作为产物：
  描述：

  4-叔丁氧羰基氨基哌啶 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-(4-nitrobenzenesulfonyl)piperidin-4-ylamine
  参考文献：
  名称：

  TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

  摘要：

  本文提供了某些化合物和药用盐。还提供了包含至少一种化合物或药用盐以及一个或多个药用载体的药物组合物。描述了治疗对转谷氨酰胺酶TG2活性抑制敏感的某些疾病状态的方法。这些疾病状态包括亚型汉廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化合物或药用盐作为单一活性剂或与一个或多个其他治疗剂结合使用至少一种化合物或药用盐。

  公开号：

  US20120302539A1

文献信息

• Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
  申请人：Prime Michael

  公开号：US08889716B2

  公开（公告）日：2014-11-18

  Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

  本文提供了某些化合物和药用可接受盐。还提供了制药组合物，其中包括至少一种化合物或药用可接受盐以及一个或多个药用可接受载体。描述了治疗对转谷氨酰胺酶TG2活性抑制有反应的某些疾病状态的方法。这些疾病状态包括神经退行性疾病，如亨廷顿病。还描述了治疗方法，包括单独使用至少一种化合物或药用可接受盐作为活性剂，或与一个或多个其他治疗剂联合使用至少一种化合物或药用可接受盐。
• Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3β inhibitors to activate Wnt/β-catenin pathway
  作者：Hong Yue、Feng Lu、Chen Shen、Jun-Min Quan

  DOI：10.1016/j.bioorg.2015.05.009

  日期：2015.8

  Deregulation of Wnt/beta-catenin pathway is closely related to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD), and glycogen synthase kinase 3 beta (GSK-3 beta), the central negative regulator of Wnt pathway, is regarded as an important target for these diseases. Here, we report a series of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3 beta inhibitors by rational-design and synthesis, which show high selectivity against GSK-3 beta over Cyclin-dependent kinase 2 (CDK2), and significantly activate the cellular Wnt/beta-catenin pathway. The structure-activity relationship of these GSK-3 beta inhibitors was also explored by in silico molecular docking. (C) 2015 Elsevier Inc. All rights reserved.
• Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease
  作者：Michael E. Prime、Frederick A. Brookfield、Stephen M. Courtney、Simon Gaines、Richard W. Marston、Osamu Ichihara、Marie Li、Darshan Vaidya、Helen Williams、Anna Pedret-Dunn、Laura Reed、Sabine Schaertl、Leticia Toledo-Sherman、Maria Beconi、Douglas Macdonald、Ignacio Muñoz-Sanjuan、Celia Dominguez、John Wityak

  DOI：10.1021/ml3001352

  日期：2012.9.13

  A new series of potent TG2 inhibitors are reported that employ a 4-aminopiperidine core bearing an acrylamide warhead. We establish the structure activity relationship of this new series and report on the transglutaminase selectivity and in vitro ADME properties of selected compounds. We demonstrate that the compounds do not conjugate glutathione in an in vitro setting and have superior plasma stability over our previous series.
• US8889716B2
  申请人：——

  公开号：US8889716B2

  公开（公告）日：2014-11-18
• [EN] CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS DE CDK ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：[en]RISEN (SUZHOU) PHARMA TECH CO., LTD.

  公开号：WO2023205892A1

  公开（公告）日：2023-11-02

  The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group (1a), 1b) and (1c), that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers. Formulas (1a), (1b) & (1c):